Bayer's new blood thinning drug passes safety tests

By Admin
A new drug which has been manufactured by the German pharmaceutical company Bayer has proved to be just as successful as warfarin in preventing strokes...

A new drug which has been manufactured by the German pharmaceutical company Bayer has proved to be just as successful as warfarin in preventing strokes.

The blood thinner Xarelto, which is also known as Rivaroxaban, has just undergone phase three clinical safety tests during a Japanese study.

The results of the study are being reported as positive, after it was found that it did not raise the risk of bleeding in Japanese stroke patients.

READ MORE FROM THE WDM CONTENT NETWORK:

To read the latest edition of Healthcare Global, click here

In a statement Bayer said of the results: "It is important that Rivaroxaban demonstrated non-inferior safety and that there were numerically fewer intracranial hemorrhages versus warfarin.”

 The company has been seeking Japanese approval to market the Rivaroxaban drug for treating patients with irregular heartbeats since April.

 Bayer believes potential sales of the blood thinning treatment could total US$2.3 billion each year, which is equivalent to €2 billion.

The drug was developed in partnership with Johnson & Johnson and it already sells in 110 countries across the world. 

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals